Launch week offerEnds in00h00m00s

annual Promonthly Pro

Gilles Peytavin

Université Paris Cité

France

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in France

Articles (10)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Collaborators (5)

Laurent Mandelbrot

Université Paris Cité

FRANCE

View details

Jean‐Marc Treluyer

Assistance Publique - Hôpitaux de Paris

FRANCE

View details

Nicolas Venisse

Professeur des Universités - Praticien Hospitalier (PU-PH)

University of Poitiers

FRANCE

View details

Constance Delaugerre

Paris university

FRANCE

View details

Thomas Stehlé

Assistance Publique - Hôpitaux de Paris

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gilles Peytavin

Research Interests

Make your next move.

Explore related searches

Articles (10)

Drug–drug interaction between praziquantel and nevirapine in HIV-schistosomiasis co-infection: a pharmacokinetic case report

Effectiveness and Safety of Lenacapavir-Containing Regimens in Highly Experienced HIV-Infected Patients With Multidrug Resistance: Real-world Results From the French Compassionate Use Program

Maternal-Fetal Letermovir Exposure In Vivo and Physiologically Based Pharmacokinetic Modeling: A Rationale for Congenital Cytomegalovirus Therapy

Drug interactions and kidney safety of bictegravir/emtricitabine/tenofovir alafenamide in kidney transplant recipients with HIV: an interventional pilot study

HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir

How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?

Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model

Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing Regimen

Population pharmacokinetics of aciclovir and its major metabolite 9-carboxymethoxymethylguanine and safety profile of valaciclovir in early liver transplant recipients

Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV

Collaborators (5)

Laurent Mandelbrot

Jean‐Marc Treluyer

Nicolas Venisse

Constance Delaugerre

Thomas Stehlé

Make your next move.